FRLN

6.40 USD
-0.08 (-1.23%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

stock is down -1.23% since 30 days ago. The next earnings date is Jul 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 3 June’s closed higher than May.

About

Freeline Therapeutics Holdings plc develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B.